Fig. 3: Effective P-BCMA-ALLO1 cells exhibit high proliferative capacity and functionality. | Nature Communications

Fig. 3: Effective P-BCMA-ALLO1 cells exhibit high proliferative capacity and functionality.

From: TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial

Fig. 3

A Serial restimulation of P-BCMA-ALLO1 with irradiated K562-BCMA cells distinguished lots based on their Ag-specific proliferative capacity. B After restimulation, P-BCMA-ALLO1 cells showed a more differentiated phenotype while predominantly retaining a TCM phenotype. C Maximum fold expansion from serial restimulation was significantly correlated with tumor control (n = 25 lots; ineffective or <50% tumor control [blue]; effective or ≥50% tumor control [red]). D, E Phenotypic analysis of single-cell cytokine secretion of CD8+ cells in P-BCMA-ALLO1 activated against K562-BCMA cells (E:T = 2) identified six distinct clusters with varied cytokine profiles among P-BCMA-ALLO1 cells (n = 21 lots). F The frequency of IFNγhi “super secretors” and (G) the PSI both positively correlated with tumor control. Statistical analysis performed in (C), (F), (G) used a two-sided t-test. Source data are provided as a Source Data file.

Back to article page